The role of cell-free DNA size distribution in the management of prostate cancer

Oncology Research

Volumn 16, Issue 1, 2006, Pages 35-41

  Boddy, Jane L ^a   Gal, Shira ^b   Malone, Peter R ^a   Shaida, Nadeem ^a   Wainscoat, James S ^b   Harris, Adrian L ^c,d  

^a ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Cell free DNA; Prostate cancer; Size distribution

Indexed keywords

ARTICLE; CANCER STAGING; CELL FREE SYSTEM; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; RANK SUM TEST; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TUMOR BIOPSY;

EID: 33746906698     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000006783981297     Document Type: Article

References (19)

1. Partin, A. W.; Carter, H. B.; Chan, D. W.; Epstein, J. I.; Oesterling, J. E.; Rock, R. C.; Weber, J. P.; Walsh, P. C. Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia. J. Urol. 143:747-752; 1990.
2. Nadler, R. B.; Humphrey, P. A.; Smith, D. S.; Catalona, W. J.; Ratliff, T. L. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J. Urol. 154:407-413; 1995.
3. Fleshner, N. E.; O'Sullivan, M.; Fair, W. R. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J. Urol. 158:505-508; 1997.
4. Rabbani, F.; Stroumbakis, N.; Kava, B. R.; Cookson, M. S.; Fair, W. R. Incidence and clinical significance of false-negative sextant prostate biopsies. J. Urol. 159:1247-1250; 1998.
5. Leon, S. A.; Shapiro, B.; Sklaroff, D. M.; Yaros, M. J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37:646-650; 1977.
6. Shapiro, B.; Chakrabarty, M.; Cohn, E. M.; Leon, S. A. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 51:2116-2120; 1983.
7. Sozzi, G.; Conte, D.; Mariani, L.; Lo Vullo, S.; Roz, L.; Lombardo, C.; Pierotti, M. A.; Tavecchio, L. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 61:4675-4678; 2001.
8. Wu, T. L.; Zhang, D.; Chia, J. H.; Tsao, K. H.; Sun, C. F.; Wu, J. T. Cell-free DNA: Measurement in various carcinomas and establishment of normal reference range. Clin. Chim. Acta 321:77-87; 2002.
9. Mulcahy, H. E.; Lyautey, J.; Lederrey, C.; qi Chen, X.; Anker, P.; Alstead, E. M.; Ballinger, A.; Farthing, M. J.; Stroun, M. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin. Cancer Res. 4:271-275; 1998.
10. Nawroz, H.; Koch, W.; Anker, P.; Stroun, M.; Sidransky, D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat. Med. 2:1035-1037; 1996.
11. Goessl, C.; Krause, H.; Muller, M.; Heicappell, R.; Schrader, M.; Sachsinger, J.; Miller, K. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res. 60:5941-5945; 2000.
12. Giacona, M. B.; Ruben, G. C.; Iczkowski, K. A.; Roos, T. B.; Porter, D. M.; Sorenson, G. D. Cell-free DNA in human blood plasma: Length measurements in patients with pancreatic cancer and healthy controls. Pancreas 17:89-97; 1998.
13. Wang, B. G.; Huang, H. Y.; Chen, Y. C.; Bristow, R. E.; Kassauei, K.; Cheng, C. C.; Roden, R.; Sokoll, L. J.; Chan, D. W.; Shih Ie, M. Increased plasma DNA integrity in cancer patients. Cancer Res. 63:3966-3968; 2003.
14. Boynton, K. A.; Summerhayes, I. C.; Ahlquist, D. A.; Shuber, A. P. DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin. Chem. 49:1058-1065; 2003.
15. Gunnarsson, C.; Ahnstrom, M.; Kirschner, K.; Olsson, B.; Nordenskjold, B.; Rutqvist, L. E.; Skoog, L.; Stal, O. Amplification of HSD17B1 and ERBB2 in primary breast cancer. Oncogene 22:34-40; 2003.
16. Lo, Y. M.; Tein, M. S.; Lau, T. K.; Haines, C. J.; Leung, T. N.; Poon, P. M.; Wainscoat, J. S.; Johnson, P. J.; Chang, A. M.; Hjelm, N. M. Quantitative analysis of fetal DNA in maternal plasma and serum: Implications for noninvasive prenatal diagnosis. Am. J. Hum. Genet. 62:768-775; 1998.
17. Chan, K. C.; Zhang, J.; Hui, A. B.; Wong, N.; Lau, T. K.; Leung, T. N.; Lo, K. W.; Huang, D. W.; Lo, Y. M. Size distributions of maternal and fetal DNA in maternal plasma. Clin. Chem. 50:88-92; 2004.
18. Boddy, J. L.; Gal, S.; Malone, P. R.; Harris, A. L.; Wainscoat, J. S. Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease. Clin. Cancer Res. 11:1394-1399; 2005.
19. Chiu, R. W.; Poon, L. L.; Lau, T. K.; Leung, T. K.; Wong, E. M.; Lo, Y. M. Effects of blood-processing protocols on fetal and total DNA quantification in maternal plasma. Clin. Chem. 47:1607-1613; 2001.